Clinical trial

Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)

NCT07264647

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2025-03-27

PhasePHASE2

Study timeline

Study start (actual)2025-03-27Date precision: day

Registry last updated2025-12-04

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Stage III NSCLCunresolved

Interventions

TislelizumabDRUG · verified · RxNorm: tislelizumab

surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelinesPROCEDURE

ChemoradiotherapyRADIATION

Sponsors & collaborators

Fondazione Ricerca Traslazionalelead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07264647 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.